New Issue: Science’s Impossible Questions. Read Now

Guinea to Expand Use of Experimental Anti-Ebola Drugs

Guinea's government has authorized the wider use of an experimental drug to treat Ebola in treatment centers after successful initial trials, officials said

Join Our Community of Science Lovers!

CONAKRY (Reuters) - Guinea's government has authorized the wider use of an experimental drug to treat Ebola in treatment centers after successful initial trials, officials said on Saturday.

The expansion of the treatment comes as the number of people with Ebola in Guinea has doubled in the past week, reversing a broader trend of decline across the three worst-hit West African states - Guinea, Liberia and Sierra Leone.

The experimental Japanese drug - Avigan, or favipiravir - developed by Toyama Chemical, a subsidiary of Japan's Fujifilm, has been tested by French and Guinean teams in southern Guinea since mid-December.


On supporting science journalism

If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.


French President Francois Hollande's office said on Wednesday that the results had been positive and the drug appeared to accelerated the recovery process of patients.

"We have decided to broaden the use of this drug. It will only be available in the Ebola Treatment Units, not the hospitals," Sakoba Keita, coordinator of Guinea's Ebola response, told reporters on Saturday.

Guinea's anti-Ebola task force said about two dozen new cases of Ebola had been recorded in the last two weeks, taking the total number to 53 as of Friday. Officials are accessing villages where they had previously faced local resistance to their presence.

Health officials have not provided any data for the results of the trials of the anti-Ebola drug.

Keita said that after testing in Gueckedou and Nzerekore, favipiravir has been distributed to the town of Coyah and talks are underway start treatment in the capital, Conakry.

"We are looking to see how we can get it to other parts of the country too," he said.

The epidemic has killed nearly 9,000 people over the last year, mainly in the three worst-affected West African nations.

Guinea, where the outbreak began, has recorded over 1,900 dead from some 3,000 confirmed cases.

"The Ebola situation is getting better but we are not cured," said Jean-François Delfraissy, a French Ebola expert working alongside Guinean authorities to contain the crisis.

 

(Reporting by Saliou Samb. Writing by David Lewis, editing by Mike Peacock)

Subscribe to Support Independent Journalism

Great science journalism requires human expertise, time, effort and creativity. And it costs money. That’s why I and the journalists here at Scientific American hope you’ll join our community.

When you subscribe, you are supporting staff and freelance journalists who are passionate about telling science stories that are true, important and compelling. Our editors and reporters are often experts in their fields, which means they understand the nuances of big discoveries and can untangle the breakthroughs from the hype. With a subscription, you are also supporting rigorous fact-checking to ensure the words we publish are precise and accurate. And you’re supporting original illustrations, graphics and photos that bring you closer to an advanced laboratory, an ice sheet in Antarctica or a space mission in orbit. You’re helping us craft other types of high-quality journalism as well: Our newsletters are carefully written, edited and curated by staffers you have or will come to know and love. Our Science Quickly podcast is based on original reporting, collaboration with editors and scientists and exacting production.

Subscriptions keep this engine running so we can continue to deliver thoughtful, rigorous and independent science journalism to you. In an era of viral misinformation, this work is crucial. If you value what we do, I hope you’ll consider joining us as a subscriber

Thank you,

Jeanna Bryner, Editor in Chief, Scientific American

Subscribe